Zydus Cadila announced that the WHO INN committee has granted the name Desidustat to its Phase II anemia candidate, ZYANI. The INN system aims to provide healthcare professionals with a universal designated name for each pharmaceutical substance. Desidustat is an oral small molecule that has been designed to inhibit hypoxia-inducible factor prolyl hydroxylase, and thereby increase the natural production of hemoglobin and RBCs in anemic patients. The molecule has been shown to improve iron mobilization and has the potential to reduce or eliminate the need for iron supplementation. Desidustat has the potential to bring about a paradigm shift in the management of patients with anemia as it could provide an oral, safer alternative to currently available erythropoietin-stimulating agents (ESAs), which are associated with an increased risk of CV events and must be given through injections.